Overstimulation of NMDA receptors impairs early brain development in vivo

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Aida, Tomomi ^a   Ito, Yoshimasa ^a   Takahashi, Yuko K ^a   Tanaka, Kohichi ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; EXCITATORY AMINO ACID TRANSPORTER 1; MICROTUBULE ASSOCIATED PROTEIN 2; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; EXCITATORY AMINO ACID TRANSPORTER 2; NR1 NMDA RECEPTOR; PRIMER DNA; SLC1A2 PROTEIN, MOUSE; SLC1A3 PROTEIN, MOUSE;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN DEVELOPMENT; BRAIN DYSFUNCTION; BRAIN NERVE CELL; CONTROLLED STUDY; DISORIENTATION; EMBRYO; HIPPOCAMPUS; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; MUTATION; NERVE PROJECTION; NERVE STIMULATION; NEUROLOGIC DISEASE; NONHUMAN; OLFACTORY BULB; PROTEIN DEPLETION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; THALAMOCORTICAL TRACT; ANIMAL; BRAIN; CONGENITAL MALFORMATION; FEMALE; GENETICS; METABOLISM; MOUSE MUTANT; NUCLEOTIDE SEQUENCE; PREGNANCY; PRENATAL DEVELOPMENT;

MUS;

ANIMALS; BASE SEQUENCE; BRAIN; CEREBRAL CORTEX; DNA PRIMERS; EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; FEMALE; HIPPOCAMPUS; MICE; MICE, KNOCKOUT; OLFACTORY BULB; PREGNANCY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84860990369     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036853     Document Type: Article

References (36)

1. Fantemi SH, Folsom TD, (2009) The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 35: 528-548.
2. Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, et al. (2010) Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 13: 76-83.
3. Javitt DC, Zukin SR, (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
4. Krystal JH, Karper LP, Seibyl JP, FreemanGK, DelaneyR, et al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
5. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, et al. (1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17: 141-150.
6. Goff DC, Coyle JT, (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158: 1367-1377.
7. Arguello PA, Gogos JA, (2006) Modeling madness in mice: One piece at a time. Neuron 52: 179-196.
8. Gainetdinov RR, Mohn AR, Caron MG, (2001) Genetic animal models: Focus on schizophrenia. Trends Neurosci 24: 527-533.
9. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat Med 13: 1102-1107.
10. Yizhar O, Fenno LE, Prigge M, Schneider F, Davidson TJ, et al. (2011) Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 477: 171-178.
11. Harrison PJ, (1999) The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122: 593-624.
12. Arnold SE, (2000) Cellular and molecular neuropathology of the parahippocampal region in schizophrenia. Ann N Y Acad Sci 911: 275-292.
13. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, et al. (2003) White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 60: 443-456.
14. Volpe JJ, (2001) Perinatal brain injury: from pathogenesis to neuroprotection. Ment Retard Dev Disabil Res Rev 7: 56-64.
15. Matsugami TR, Tanemura K, Mieda M, Nakatomi R, Yamada K, et al. (2006) Indispensability of the glutamate transporters GLAST and GLT1 to brain development. Proc Natl Acad Sci U S A 103: 12161-12166.
16. Watanabe M, Inoue Y, Sakimura K, Mishina M, (1992) Developmental changes in distribution of NMDA receptor channel subunit mRNAs. Neuroreport 3: 1138-1140.
17. Monyer H, Seeburg PH, Wisden W, (1991) Glutamate-operated channels: developmentally early and mature forms arise by alternative splicing. Neuron 6: 799-810.
18. Bahn S, Volk B, Wisden W, (1994) Kainate receptor gene expression in the developing rat brain. J Neurosci 14: 5525-5547.
19. Shigemoto R, Nakanishi S, Mizuno N, (1992) Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: an in situ hybridization study in adult and developing rat. J Comp Neurol 322: 121-135.
20. Li Y, Erzurumlu RS, Chen C, Jhaveri S, Tonegawa S, (1994) Whisker-related neuronal patterns fail to develop in the trigeminal brainstem nuclei of NMDAR1 knockout mice. Cell 76: 427-437.
21. Aamodt SM, Shi J, Colonnese MT, Veras W, Constantine-Paton M, (2000) Chronic NMDA exposure accelerates development of GABAergic inhibition in the superior colliculus. J Neurophysiol 83: 1580-1591.
22. Ben-Ari Y, (2002) Excitatory actions of gaba during development: the nature of the nurture. Nat Rev Neurosci 3: 718-739.
23. Kolevzon A, Gross R, Reichenberg A, (2007) Prenatal and perinatal risk factors for autism: a review and integration of findings. Arch Pediatr Adolesc Med 161: 326-333.
24. Schmidt-Kastner R, van Os J, Steinbusch HMW, Schmitz C, (2006) Gene regulation by hypoxia and the neurodevelopmental origin of schizophrenia. Schizophr Res 84: 253-271.
25. Weidenhofer J, Bowden NA, Scott RJ, Tooney PA, (2006) Altered gene expression in the amygdala in schizophrenia: up-regulation of genes located in the cytomatrix active zone. Mol Cell Neurosci 31: 243-250.
26. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, et al. (2008) Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320: 539-543.
27. Karlsson RM, Tanaka K, Heilig M, Holmes A, (2008) Loss of glial glutamate and aspartate transporter (excitatory amino acid transporter 1) causes locomotor hyperactivity and exaggerated responses to psychotomimetics: rescue by haloperidol and metabotropic glutamate 2/3 agonist. Biol Psychiatry 64: 810-814.
28. Karlsson RM, Tanaka K, Saksida LM, Bussey TJ, Heilig M, et al. (2009) Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia. Neuropsychopharmacology 34: 1578-1589.
29. Xu S, Han JC, Morales A, Menzie CM, Williams K, et al. (2008) Characterization of 11p14-p12 deletion in WAGR syndrome by array CGH for identifying genes contributing to mental retardation and autism. Cytogenet Genome Res 122: 181-187.
30. Autism Genome Project Consortium, Szatmari P, Paterson AD, Zwaigenbaum L, Roberts W, et al. (2007) Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet 39: 319-328.
31. Homayoun H, Moghaddam B, (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27: 11496-11500.
32. Jackson ME, Homayoun H, Moghaddam B, (2004) NMDA receptor hypo- function produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad SciUSA101: 8467-8472.
33. Kargieman L, Santana N, Mengod G, Celada P, Artigas F, (2007) Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc Natl Acad SciUSA 104: 14843-14848.
34. Watase K, Hashimoto K, Kano M, Yamada K, Watanabe M, et al. (1998) Motor discoordination and increased susceptibility to cerebellar injury in GLAST mutant mice. Eur J Neurosci 10: 976-988.
35. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, et al. (1997) Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276: 1699-1702.
36. Iwasato T, Erzurumlu RS, Huerta PT, Chen DF, Sasaoka T, et al. (1997) NMDA receptor-dependent refinement of somatotopic maps. Neuron 19: 1201-1210.